Trial · NCT02564263
Adverse events672
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 672
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab First Course | 52 | 314 | 60 |
| other | Anaemia | Blood and lymphatic system disorders | Chemotherapy | 83 | 296 | 110 |
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab Second Course | 1 | 5 | 2 |
| other | Neutropenia | Blood and lymphatic system disorders | Pembrolizumab First Course | 0 | 314 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | Chemotherapy | 36 | 296 | 65 |
| other | Neutropenia | Blood and lymphatic system disorders | Pembrolizumab Second Course | 0 | 5 | 0 |
| other | Hypothyroidism | Endocrine disorders | Pembrolizumab First Course | 37 | 314 | 40 |
| other | Hypothyroidism | Endocrine disorders | Chemotherapy | 7 | 296 | 7 |
| other | Hypothyroidism | Endocrine disorders | Pembrolizumab Second Course | 1 | 5 | 1 |
| other | Abdominal distension | Gastrointestinal disorders | Pembrolizumab First Course | 7 | 314 | 7 |
| other | Abdominal distension | Gastrointestinal disorders | Chemotherapy | 2 | 296 | 2 |
| other | Abdominal distension | Gastrointestinal disorders | Pembrolizumab Second Course | 1 | 5 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Pembrolizumab First Course | 34 | 314 | 36 |
| other | Abdominal pain | Gastrointestinal disorders | Chemotherapy | 27 | 296 | 32 |
| other | Abdominal pain | Gastrointestinal disorders | Pembrolizumab Second Course | 0 | 5 | 0 |
| other | Abdominal pain upper | Gastrointestinal disorders | Pembrolizumab First Course | 14 | 314 | 16 |
| other | Abdominal pain upper | Gastrointestinal disorders | Chemotherapy | 17 | 296 | 19 |
| other | Abdominal pain upper | Gastrointestinal disorders | Pembrolizumab Second Course | 0 | 5 | 0 |
| other | Constipation | Gastrointestinal disorders | Pembrolizumab First Course | 56 | 314 | 63 |
| other | Constipation | Gastrointestinal disorders | Chemotherapy | 56 | 296 | 63 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02564263/events